Survival Outcomes for Patients with Metastatic Triple-Negative Breast Cancer: Implications for Clinical Practice and Trial Design
作者： Farrah Kassam , Katherine Enright , Rebecca Dent , George Dranitsaris , Jeff Myers
关键词:
摘要: … shorter disease-free survival and overall survival (OS) times.Dent et … (hazard ratio [HR], 2.6) and death (HR, 3.2) within 5 years of … 5 years), as was survival time from diagnosis of distant …
elsevier.com
metapress.com参考文章(24)
Jenny Chang, Gary M. Clark, D. Craig Allred, Syed Mohsin, Gary Chamness, Richard M. Elledge, Survival of patients with metastatic breast carcinoma: importance of prognostic markers of the primary tumor. Cancer. ,vol. 97, pp. 545- 553 ,(2003) , 10.1002/CNCR.11083
S Banerjee, Basal-like breast carcinomas: clinical outcome and response to chemotherapy Journal of Clinical Pathology. ,vol. 59, pp. 729- 735 ,(2006) , 10.1136/JCP.2005.033043
Amelia Insa, Ana Lluch, Felipe Prosper, Isabel Marugan, Angel Martinez‐Agullo, Javier Garcia‐Conde, Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: analysis of 439 patients Breast Cancer Research and Treatment. ,vol. 56, pp. 67- 78 ,(1999) , 10.1023/A:1006285726561
Emad A. Rakha, Maysa E. El-Sayed, Andrew R. Green, Andrew H. S. Lee, John F. Robertson, Ian O. Ellis, Prognostic markers in triple-negative breast cancer Cancer. ,vol. 109, pp. 25- 32 ,(2007) , 10.1002/CNCR.22381
Katrina R. Bauer, Monica Brown, Rosemary D. Cress, Carol A. Parise, Vincent Caggiano, Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer. ,vol. 109, pp. 1721- 1728 ,(2007) , 10.1002/CNCR.22618
Chad A Livasy, Gamze Karaca, Rita Nanda, Maria S Tretiakova, Olufunmilayo I Olopade, Dominic T Moore, Charles M Perou, Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma. Modern Pathology. ,vol. 19, pp. 264- 271 ,(2006) , 10.1038/MODPATHOL.3800528
Charles H. Nash, Stephen E. Jones, Thomas E. Moon, Steward L. Davis, Sydney E. Salmon, Prediction of outcome in metastatic breast cancer treated with adriamycin combination chemotherapy Cancer. ,vol. 46, pp. 2380- 2388 ,(1980) , 10.1002/1097-0142(19801201)46:11<2380::AID-CNCR2820461113>3.0.CO;2-M
Mario Rabinovich, Carlos Vallejo, Adrian Bianco, Juan Perez, Mario Machiavelli, Bernardo Leone, Alberto Romero, Ricardo Rodriguez, Maria Cuevas, Claudio Dansky, Francisco Xynos, Luis Alvarez, Development and validation of prognostic models in metastatic breast cancer: a GOCS study. Oncology. ,vol. 49, pp. 188- 195 ,(1992) , 10.1159/000227037
Rebecca Dent, Wedad M. Hanna, Maureen Trudeau, Ellen Rawlinson, Ping Sun, Steven A. Narod, Pattern of metastatic spread in triple-negative breast cancer Breast Cancer Research and Treatment. ,vol. 115, pp. 423- 428 ,(2009) , 10.1007/S10549-008-0086-2
Sunil Verma, Nan Soon Wong, Maureen Trudeau, Anil Joy, John Mackey, George Dranitsaris, Mark Clemons, Survival differences observed in metastatic breast cancer patients treated with capecitabine when compared with vinorelbine after pretreatment with anthracycline and taxane. American Journal of Clinical Oncology. ,vol. 30, pp. 297- 302 ,(2007) , 10.1097/01.COC.0000258125.97090.3F